The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence

被引:59
|
作者
Xiang, Yu-zhu [1 ]
Xiong, Hui [1 ]
Cui, Zi-lian [1 ]
Jiang, Shao-bo [1 ]
Xia, Qing-hua [1 ]
Zhao, Yong [1 ]
Li, Guan-bin [1 ]
Jin, Xun-bo [1 ]
机构
[1] Shandong Univ, Prov Hosp, Minimally Invas Urol Ctr, Jinan 250021, Peoples R China
关键词
Gleason score; Recurrence; Clinical stage; Aggressiveness; COHORT; IMPACT; MEN;
D O I
10.1186/1756-9966-32-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although a previous meta-analysis reported no association between metabolic syndrome (MetS) and prostate cancer risk, a number of studies suggest that MetS may be associated with the aggressiveness and progression of prostate cancer. However, these results have been inconsistent. This systematic review and meta-analysis investigated the nature of this association. Methods: We systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to January 2013 using the keywords "metabolic syndrome" and "prostate cancer". We assessed relative risks (RRs) of the prostate cancer, several parameters of prostate cancer aggressiveness and progression associated with MetS using 95% confidence intervals (95% CIs). Results: The literature search produced 547 hits from which 19 papers were extracted for the meta-analysis. In cancer-free population with and without MetS, the combined adjusted RR (95% CI) of prostate cancer risk and prostate cancer-specific mortality in longitudinal cohort studies is 0.96 (0.85 similar to 1.09) and 1.12 (1.02 similar to 1.23) respectively. In the prostate cancer patients with and without MetS, the combined unadjusted OR (95% CI) of high grade Gleason prostate cancer is 1.44 (1.20 similar to 1.72), the OR of advanced prostate cancer is 1.37 (1.12 similar to 1.68) and the OR of biochemical recurrence is 2.06 (1.43 similar to 2.96). Conclusions: The overall analyses revealed no association between MetS and prostate cancer risk, although men with MetS appear more likely to have high-grade prostate cancer and more advanced disease, were at greater risk of progression after radical prostatectomy and were more likely to suffer prostate cancer-specific death. Further primary studies with adjustment for appropriate confounders and larger, prospective, multicenter investigations are required.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] BASELINE PROSTATE SPECIFIC ANTIGEN LEVEL AND THE RISK OF PROSTATE CANCER AND PROSTATE SPECIFIC MORTALITY
    Connolly, D.
    Black, A.
    Van Leeuwen, P. J.
    Gavin, A.
    Murray, L. J.
    Keane, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 164 - 164
  • [32] Association of Race and Ethnicity With Prostate Cancer-Specific Mortality in Canada
    Stern, Noah
    Ly, Tina Luu
    Welk, Blayne
    Chin, Joseph
    Ballucci, Dale
    Haan, Michael
    Power, Nicholas
    JAMA NETWORK OPEN, 2021, 4 (12) : E2136364
  • [33] Baseline prostate specific antigen level and the risk of prostate cancer and prostate specific mortality
    Connolly, D. J.
    Black, A.
    Van Leeuwen, P. V.
    Gavin, A.
    Murray, L. J.
    Keane, P. F.
    BJU INTERNATIONAL, 2009, 103 : 12 - 12
  • [34] New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence
    Jonathan I Epstein
    British Journal of Cancer, 2016, 114 : 1069 - 1070
  • [35] New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence
    Epstein, Jonathan I.
    BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1069 - 1070
  • [36] Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer
    Xiang, Michael
    Nguyen, Paul L.
    BRACHYTHERAPY, 2015, 14 (06) : 773 - 780
  • [37] Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen
    Fankhauser, Christian D.
    Penney, Kathryn L.
    Gonzalez-Feliciano, Amparo G.
    Clarke, Noel W.
    Hermanns, Thomas
    Stopsack, Konrad H.
    Fiorentino, Michelangelo
    Loda, Massimo
    Mahal, Brandon
    Gerke, Travis A.
    Preston, Mark A.
    Mucci, Lorelei A.
    EUROPEAN UROLOGY, 2020, 78 (04) : 637 - +
  • [38] THE ASSOCIATION BETWEEN FINASTERIDE USE AND HIGH-GRADE OR LETHAL PROSTATE CANCER
    Preston, Mark A.
    Wilson, Katherine
    Coseo-Markt, Sarah
    Ge, Rongbin
    Giovannucci, Edward
    Morash, Christopher
    Stampfer, Meir
    Loda, Massimo
    Mucci, Lorelei A.
    Olumi, Aria F.
    JOURNAL OF UROLOGY, 2013, 189 (04): : E94 - E94
  • [39] Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: A search database study
    Freedland, SJ
    Isaacs, WB
    Platz, EA
    Terris, MK
    Aronson, WJ
    Amling, CL
    Presti, JC
    Kane, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7546 - 7554
  • [40] Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
    Hayman, Jonathan
    Phillips, Ryan
    Chen, Di
    Perin, Jamie
    Narang, Amol K.
    Trieu, Janson
    Radwan, Noura
    Greco, Stephen
    Deville, Curtiland, Jr.
    McNutt, Todd
    Song, Daniel Y.
    DeWeese, Theodore L.
    Tran, Phuoc T.
    PROSTATE, 2018, 78 (08): : 623 - 630